Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL9785253 | 1.00 | NAPRT (0.47) | NAPRTTSHRTDP1CA2GRIN1 | |
| Pyridine SCHEMBL22261991 | 0.88 | NAPRT (0.41) | NAPRTTSHRTDP1 | |
| Pyridine SCHEMBL8873439 | 0.87 | NAPRT (0.36) | NAPRTTSHRTDP1GRIN1GRIN2B | |
| Pyridine SCHEMBL2424840 | 0.84 | NAPRT (0.38) | NAPRTTSHRTDP1 | |
| Pyridine SCHEMBL28257184 | 0.84 | CA2 (0.53) | NAPRTTSHRTDP1CA2GRIN1 | |
| Pyridine SCHEMBL2424842 | 0.84 | CA2 (0.53) | NAPRTTSHRTDP1CA2GRIN1 | |
| Pyrimidine SCHEMBL21056189 | 0.84 | NAPRT (0.37) | NAPRTCA2 | |
| Pyridine SCHEMBL984983 | 0.83 | TSHR (0.53) | NAPRTTSHRTDP1GRIN1GRIN2B | |
| Pyridine SCHEMBL22261964 | 0.83 | NAPRT (0.60) | NAPRTTSHRTDP1MAPTMEN1 | |
| Pyridine SCHEMBL22261990 | 0.83 | NAPRT (0.60) | NAPRTTSHRTDP1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116063360-A | Disaccharide polysulfate for improving skin function, and preparation method and application thereof | 麦吉丽生物科技有限公司 | 2023-05-05 | — | — | CN | claimed |
| US-9394378-B2 | Process for obtaining chondroitin sulphated at the 4- or 6- positions of N-acetyl-galactosamine residues | ALTERGON S.A. (CH) | 2016-07-19 | — | — | US | claimed |
| CN-103298837-B | Obtain the method at the Sulfated chrondroitin in 4-or 6-position of GalNAc residue | ALTERGON S.A. (CH) | 2016-01-20 | — | — | CN | claimed |
| EP-2638074-B1 | PROCESS FOR OBTAINING CHONDROITIN SULPHATED AT THE 4- OR 6- POSITIONS OF N-ACETYL-GALACTOSAMINE RESIDUES | ALTERGON SA (CH) | 2015-01-07 | — | — | EP | claimed |
| EP-2638074-A2 | PROCESS FOR OBTAINING CHONDROITIN SULPHATED AT THE 4- OR 6- POSITIONS OF N-ACETYL-GALACTOSAMINE RESIDUES | Altergon S.a. (CH) | 2013-09-18 | — | — | EP | claimed |
| CN-103298837-A | Process for obtaining chondroitin sulphated at the 4- or 6- positions of n-acetyl-galactosamine residues | ALTERGON SA | 2013-09-11 | — | — | CN | claimed |
| US-20130225802-A1 | PROCESS FOR OBTAINING CHONDROITIN SULPHATED AT THE 4- OR 6- POSITIONS OF N-ACETYL-GALACTOSAMINE RESIDUES | ALTERGON S.A. (CH) | 2013-08-29 | — | — | US | claimed |
| WO-2012062917-A2 | PROCESS FOR OBTAINING CHONDROITIN SULPHATED AT THE 4- OR 6- POSITIONS OF N-ACETYL-GALACTOSAMINE RESIDUES | ALTERGON S.A. (CH) | 2012-05-18 | — | — | WO | claimed |
| US-20050203056-A1 | Carboxyl-reduced derivatives of hyaluronic acid, preparation thereof, use thereof as a medicinal product and the pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2005-09-15 | — | — | US | claimed |
| US-20050187187-A1 | Carboxyl-reduced derivatives of chondroitin sulfate, preparation thereof, use thereof as a medicinal product and the pharmaceutical compositions containing them | AVENTIS PHARMAS S.A. (FR) | 2005-08-25 | — | — | US | claimed |
| US-20050164983-A1 | Carboxyl-reduced derivatives of dermatan sulfate, preparation thereof, use thereof as a medicinal product and the pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2005-07-28 | — | — | US | claimed |
| WO-2003066657-A1 | A PROCESS FOR PREPARING URSODEOXYCHOLIC ACID DUSULPHATE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ABC INTERNATIONAL PHARMA S.R.L. (IT) | 2003-08-14 | — | — | WO | claimed |
| US-5254681-A | Process for preparing monobactames and their intermediate product | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1993-10-19 | — | — | US | claimed |
| EP-0411541-A2 | Process for preparing monobactames and their intermediate product | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1991-02-06 | — | — | EP | claimed |
| EP-0159026-B1 | PENTAERYTHRITOL DERIVATIVES AND A PROCESS FOR PREPARING THE SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 1988-08-24 | — | — | EP | claimed |
| EP-0107860-B1 | PEPTIDES, PROCESS FOR PREPARING THE SAME AND PSYCHODEPRESSANT COMPOSITIONS CONTAINING THE SAME | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1986-09-17 | — | — | EP | claimed |
| US-4565811-A | Sodium salt of ursodeoxycholic sulphate | ISTITUTO BIOLOGICO CHEMIOTERAPICO "ABC" S.P.A. (IT) | 1986-01-21 | — | — | US | claimed |
| EP-0159026-A2 | Pentaerythritol derivatives and a process for preparing the same | Chugai Seiyaku Kabushiki Kaisha (JP) | 1985-10-23 | — | — | EP | claimed |
| EP-0117570-A1 | Sodium salt of ursodeoxycholic sulphate | ISTITUTO BIOLOGICO CHEMIOTERAPICO "ABC" S.p.A. (IT) | 1984-09-05 | — | — | EP | claimed |
| EP-0107860-A1 | Peptides, process for preparing the same and psychodepressant compositions containing the same | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1984-05-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203056-A1 | Carboxyl-reduced derivatives of hyaluronic acid, preparation thereof, use thereof as a medicinal product and the pharmaceutical compositions containing them | CD44, H1-3, H1-0 | NAPRT 1563/4885TSHR 2065/4885TDP1 4620/4885 |
| US-20050164983-A1 | Carboxyl-reduced derivatives of dermatan sulfate, preparation thereof, use thereof as a medicinal product and the pharmaceutical compositions containing them | ACMSD, C1S, C1R | NAPRT 2343/4885TSHR 4266/4885TDP1 4729/4885 |
| US-20050187187-A1 | Carboxyl-reduced derivatives of chondroitin sulfate, preparation thereof, use thereof as a medicinal product and the pharmaceutical compositions containing them | C1S, CSGALNACT1, CS | NAPRT 1587/4885TSHR 4304/4885TDP1 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.